NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United StatesGlobeNewsWire • 10/16/25
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/04/25
NextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/07/25
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaGlobeNewsWire • 07/24/25
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6GlobeNewsWire • 06/16/25
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025GlobeNewsWire • 05/29/25
NextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/01/25
NextCure Provides Business Update and Reports Full Year 2024 Financial ResultsGlobeNewsWire • 03/06/25
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersGlobeNewsWire • 01/10/25
NextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/26/24
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaGlobeNewsWire • 11/19/24
NextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewsWire • 11/07/24
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 11/05/24
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 10/04/24
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024GlobeNewsWire • 09/16/24
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewsWire • 06/20/24
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024GlobeNewsWire • 05/30/24
NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/02/24
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024GlobeNewsWire • 04/24/24
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024GlobeNewsWire • 04/08/24